Becton Dickinson and Co (BDX) Shares Bought by Isthmus Partners LLC

Isthmus Partners LLC boosted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 1.1% during the fourth quarter, HoldingsChannel reports. The firm owned 33,600 shares of the medical instruments supplier’s stock after acquiring an additional 381 shares during the period. Becton Dickinson and makes up about 2.3% of Isthmus Partners LLC’s portfolio, making the stock its 9th largest holding. Isthmus Partners LLC’s holdings in Becton Dickinson and were worth $7,571,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC raised its stake in Becton Dickinson and by 7.6% in the 2nd quarter. FMR LLC now owns 16,067,452 shares of the medical instruments supplier’s stock worth $3,849,118,000 after acquiring an additional 1,129,688 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Becton Dickinson and during the 3rd quarter valued at about $251,000. Atria Investments LLC raised its stake in shares of Becton Dickinson and by 38.9% during the 3rd quarter. Atria Investments LLC now owns 1,488 shares of the medical instruments supplier’s stock valued at $388,000 after buying an additional 417 shares during the last quarter. First Hawaiian Bank purchased a new position in shares of Becton Dickinson and during the 3rd quarter valued at about $2,004,000. Finally, Andra AP fonden raised its stake in shares of Becton Dickinson and by 73.3% during the 3rd quarter. Andra AP fonden now owns 10,400 shares of the medical instruments supplier’s stock valued at $2,714,000 after buying an additional 4,400 shares during the last quarter. 86.28% of the stock is currently owned by hedge funds and other institutional investors.

NYSE:BDX opened at $242.21 on Monday. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $265.87. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.97. The stock has a market cap of $65.17 billion, a PE ratio of 22.00, a price-to-earnings-growth ratio of 1.70 and a beta of 1.23.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating the Zacks’ consensus estimate of $2.58 by $0.12. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The firm had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the firm earned $2.48 EPS. The company’s quarterly revenue was up 35.1% on a year-over-year basis. As a group, analysts expect that Becton Dickinson and Co will post 12.1 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date of this dividend is Thursday, March 7th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

In related news, EVP James W. Borzi sold 5,887 shares of Becton Dickinson and stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $252.37, for a total value of $1,485,702.19. Following the sale, the executive vice president now directly owns 6,013 shares in the company, valued at approximately $1,517,500.81. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Thomas E. Polen, Jr. sold 5,243 shares of Becton Dickinson and stock in a transaction dated Monday, November 19th. The stock was sold at an average price of $243.86, for a total value of $1,278,557.98. The disclosure for this sale can be found here. Insiders have sold a total of 34,606 shares of company stock worth $8,356,772 over the last 90 days. Insiders own 0.12% of the company’s stock.

A number of equities analysts have weighed in on BDX shares. TheStreet lowered Becton Dickinson and from a “b+” rating to a “c+” rating in a research note on Friday, December 7th. KeyCorp lifted their price objective on Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a research note on Thursday, November 8th. Citigroup reduced their price objective on Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating for the company in a research note on Wednesday, January 2nd. Wells Fargo & Co reduced their price objective on Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, November 7th. Finally, UBS Group started coverage on Becton Dickinson and in a research note on Tuesday, November 27th. They set a “neutral” rating and a $260.00 price objective for the company. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Becton Dickinson and has an average rating of “Buy” and a consensus target price of $253.17.

ILLEGAL ACTIVITY NOTICE: “Becton Dickinson and Co (BDX) Shares Bought by Isthmus Partners LLC” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.themarketsdaily.com/2019/02/11/becton-dickinson-and-co-bdx-shares-bought-by-isthmus-partners-llc.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: Moving Average (MA)

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply